Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study

Epi-IBD group

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

23 Downloads (Pure)

Resumé

Background and Aims: Few population-based cohort studies have assessed the disease course of ulcerative colitis [UC] in the era of biological therapy and widespread use of immunomodulators. The aim of this study was to assess the 5-year outcome and disease course of patients with UC in the Epi-IBD cohort.

Methods: In a prospective, population-based inception cohort of unselected patients with UC, patients were followed up from the time of their diagnosis, which included the collection of their clinical data, demographics, disease activity, medical therapy, and rates of surgery, cancers, and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis.

Results: A total of 717 patients were included in the study. During follow-up, 43 [6%] patients underwent a colectomy and 163 [23%] patients were hospitalised. Of patients with limited colitis [distal to the left flexure], 90 [21%] progressed to extensive colitis. In addition, 92 [27%] patients with extensive colitis experienced a regression in disease extent, which was associated with a reduced risk of hospitalisation (hazard ratio [HR]: 0.5 95% CI: 0.3-0.8]. Overall, patients were treated similarly in both geographical regions; 80 [11%] patients needed biological therapy and 210 [29%] patients received immunomodulators. Treatment with immunomodulators was found to reduce the risk of hospitalisation [HR: 0.5 95% CI: 0.3-0.8].

Conclusions: Although patients in this population-based cohort were treated more aggressively with immunomodulators and biological therapy than in cohorts from the previous two decades, their disease outcomes, including colectomy rates, were no different. However, treatment with immunomodulators was found to reduce the risk of hospitalisation.

OriginalsprogEngelsk
TidsskriftJournal of Crohn's and Colitis
Vol/bind13
Udgave nummer2
Sider (fra-til)198–208
ISSN1873-9946
DOI
StatusUdgivet - 1. feb. 2019

Fingeraftryk

Ulcerative Colitis
Population
Immunologic Factors
Colitis
Cohort Studies
Regression Analysis

Citer dette

@article{021cfa8e325d4f75a2c4a84f365b88c0,
title = "Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study",
abstract = "Background and Aims: Few population-based cohort studies have assessed the disease course of ulcerative colitis [UC] in the era of biological therapy and widespread use of immunomodulators. The aim of this study was to assess the 5-year outcome and disease course of patients with UC in the Epi-IBD cohort.Methods: In a prospective, population-based inception cohort of unselected patients with UC, patients were followed up from the time of their diagnosis, which included the collection of their clinical data, demographics, disease activity, medical therapy, and rates of surgery, cancers, and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis.Results: A total of 717 patients were included in the study. During follow-up, 43 [6{\%}] patients underwent a colectomy and 163 [23{\%}] patients were hospitalised. Of patients with limited colitis [distal to the left flexure], 90 [21{\%}] progressed to extensive colitis. In addition, 92 [27{\%}] patients with extensive colitis experienced a regression in disease extent, which was associated with a reduced risk of hospitalisation (hazard ratio [HR]: 0.5 95{\%} CI: 0.3-0.8]. Overall, patients were treated similarly in both geographical regions; 80 [11{\%}] patients needed biological therapy and 210 [29{\%}] patients received immunomodulators. Treatment with immunomodulators was found to reduce the risk of hospitalisation [HR: 0.5 95{\%} CI: 0.3-0.8].Conclusions: Although patients in this population-based cohort were treated more aggressively with immunomodulators and biological therapy than in cohorts from the previous two decades, their disease outcomes, including colectomy rates, were no different. However, treatment with immunomodulators was found to reduce the risk of hospitalisation.",
keywords = "Ulcerative colitis, biologics, hospitalisation, prognosis, surgery, treatment",
author = "Johan Burisch and Katsanos, {Konstantinos H} and Christodoulou, {Dimitrios K} and Luisa Barros and Fernando Magro and Natalia Pedersen and Jens Kjeldsen and Zsuzsanna Vegh and Lakatos, {Peter L} and Carl Eriksson and Jonas Halfvarson and Mathurin Fumery and Corinne Gower-Rousseau and Marko Brinar and Silvija Cukovic-Cavka and Inna Nikulina and Elena Belousova and Sally Myers and Shaji Sebastian and Gediminas Kiudelis and Limas Kupcinskas and Doron Schwartz and Selwyn Odes and Kaimakliotis, {Ioannis P} and Daniela Valpiani and Renata D'Inc{\`a} and Riina Salupere and Zammit, {Stefania Chetcuti} and Pierre Ellul and Dana Duricova and Martin Bortlik and Adrian Goldis and Kievit, {Hendrika Adriana Linda} and Alina Toca and Svetlana Turcan and J{\'o}nger{\dh} Midjord and Nielsen, {K{\'a}ri Rubek} and Andersen, {Karina Winther} and Vibeke Andersen and Ravi Misra and Naila Arebi and Pia Oksanen and Pekka Collin and {de Castro}, Luisa and Vicent Hernandez and Ebbe Langholz and Pia Munkholm and {Epi-IBD group}",
year = "2019",
month = "2",
day = "1",
doi = "10.1093/ecco-jcc/jjy154",
language = "English",
volume = "13",
pages = "198–208",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Heinemann",
number = "2",

}

Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. / Epi-IBD group.

I: Journal of Crohn's and Colitis, Bind 13, Nr. 2, 01.02.2019, s. 198–208.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study

AU - Burisch, Johan

AU - Katsanos, Konstantinos H

AU - Christodoulou, Dimitrios K

AU - Barros, Luisa

AU - Magro, Fernando

AU - Pedersen, Natalia

AU - Kjeldsen, Jens

AU - Vegh, Zsuzsanna

AU - Lakatos, Peter L

AU - Eriksson, Carl

AU - Halfvarson, Jonas

AU - Fumery, Mathurin

AU - Gower-Rousseau, Corinne

AU - Brinar, Marko

AU - Cukovic-Cavka, Silvija

AU - Nikulina, Inna

AU - Belousova, Elena

AU - Myers, Sally

AU - Sebastian, Shaji

AU - Kiudelis, Gediminas

AU - Kupcinskas, Limas

AU - Schwartz, Doron

AU - Odes, Selwyn

AU - Kaimakliotis, Ioannis P

AU - Valpiani, Daniela

AU - D'Incà, Renata

AU - Salupere, Riina

AU - Zammit, Stefania Chetcuti

AU - Ellul, Pierre

AU - Duricova, Dana

AU - Bortlik, Martin

AU - Goldis, Adrian

AU - Kievit, Hendrika Adriana Linda

AU - Toca, Alina

AU - Turcan, Svetlana

AU - Midjord, Jóngerð

AU - Nielsen, Kári Rubek

AU - Andersen, Karina Winther

AU - Andersen, Vibeke

AU - Misra, Ravi

AU - Arebi, Naila

AU - Oksanen, Pia

AU - Collin, Pekka

AU - de Castro, Luisa

AU - Hernandez, Vicent

AU - Langholz, Ebbe

AU - Munkholm, Pia

AU - Epi-IBD group

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Background and Aims: Few population-based cohort studies have assessed the disease course of ulcerative colitis [UC] in the era of biological therapy and widespread use of immunomodulators. The aim of this study was to assess the 5-year outcome and disease course of patients with UC in the Epi-IBD cohort.Methods: In a prospective, population-based inception cohort of unselected patients with UC, patients were followed up from the time of their diagnosis, which included the collection of their clinical data, demographics, disease activity, medical therapy, and rates of surgery, cancers, and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis.Results: A total of 717 patients were included in the study. During follow-up, 43 [6%] patients underwent a colectomy and 163 [23%] patients were hospitalised. Of patients with limited colitis [distal to the left flexure], 90 [21%] progressed to extensive colitis. In addition, 92 [27%] patients with extensive colitis experienced a regression in disease extent, which was associated with a reduced risk of hospitalisation (hazard ratio [HR]: 0.5 95% CI: 0.3-0.8]. Overall, patients were treated similarly in both geographical regions; 80 [11%] patients needed biological therapy and 210 [29%] patients received immunomodulators. Treatment with immunomodulators was found to reduce the risk of hospitalisation [HR: 0.5 95% CI: 0.3-0.8].Conclusions: Although patients in this population-based cohort were treated more aggressively with immunomodulators and biological therapy than in cohorts from the previous two decades, their disease outcomes, including colectomy rates, were no different. However, treatment with immunomodulators was found to reduce the risk of hospitalisation.

AB - Background and Aims: Few population-based cohort studies have assessed the disease course of ulcerative colitis [UC] in the era of biological therapy and widespread use of immunomodulators. The aim of this study was to assess the 5-year outcome and disease course of patients with UC in the Epi-IBD cohort.Methods: In a prospective, population-based inception cohort of unselected patients with UC, patients were followed up from the time of their diagnosis, which included the collection of their clinical data, demographics, disease activity, medical therapy, and rates of surgery, cancers, and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis.Results: A total of 717 patients were included in the study. During follow-up, 43 [6%] patients underwent a colectomy and 163 [23%] patients were hospitalised. Of patients with limited colitis [distal to the left flexure], 90 [21%] progressed to extensive colitis. In addition, 92 [27%] patients with extensive colitis experienced a regression in disease extent, which was associated with a reduced risk of hospitalisation (hazard ratio [HR]: 0.5 95% CI: 0.3-0.8]. Overall, patients were treated similarly in both geographical regions; 80 [11%] patients needed biological therapy and 210 [29%] patients received immunomodulators. Treatment with immunomodulators was found to reduce the risk of hospitalisation [HR: 0.5 95% CI: 0.3-0.8].Conclusions: Although patients in this population-based cohort were treated more aggressively with immunomodulators and biological therapy than in cohorts from the previous two decades, their disease outcomes, including colectomy rates, were no different. However, treatment with immunomodulators was found to reduce the risk of hospitalisation.

KW - Ulcerative colitis

KW - biologics

KW - hospitalisation

KW - prognosis

KW - surgery

KW - treatment

U2 - 10.1093/ecco-jcc/jjy154

DO - 10.1093/ecco-jcc/jjy154

M3 - Journal article

C2 - 30289522

VL - 13

SP - 198

EP - 208

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 2

ER -